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 Clinical and Prognostic Implications of the Genetic 
Diagnosis of Hereditary NET Syndromes in 
Asymptomatic Patients
docrine tumors and/or nontumor lesions. Some 
NET syndromes, such as MENs, are characterized 
by germline mutations usually inherited as an 
autosomal dominant disease according to the 
Knudson’s “two-hits hypothesis”  [ 4 ] . Compared 
to the sporadic forms, hereditary NETs present an 
earlier age at onset, multiple tumor localizations, 
and higher secretory activity.
 For subject identifi ed as asymptomatic mutant 
carriers for MENs, clinical, biochemical, and 
instrumental workups have been elaborated, in 
order to early detect tumors and to start a preco-
cious treatment. No workups are available for 
mutant carriers for FPGLs  [ 5 – 7 ] .
 Multiple Endocrine Neoplasias (MENs)
 ▼
 There are diﬀ erent kinds of MEN syndrome: 
MEN1, MEN2, and the recently discovered MEN4.
 MEN1 or Wermer’s Syndrome (OMIM #131100) 
is an autosomal dominant disorder characterized 
by high penetrance, variable inter- and intra-
 Introduction
 ▼
 Neuroendocrine tumors (NETs) are rare and het-
erogeneous neoplasms with variable biological 
behavior. The estimated incidence of NETs is 
about 1–5 cases/100 000/year. Recent data show 
a progressive increase of the incidence in the last 
years and a high increase of their prevalence and 
survival  [ 1 ] . NETs can be sporadic or can arise in 
complex hereditary endocrine disorders such as 
Multiple Endocrine Neoplasias (MENs), Familial 
Paragangliomatosis (FPGLs), Neurofi bromatosis 
type 1 (NF1), von Hippel–Lindau Disease (VHL), 
Tuberous Sclerosis, and Carney Complex  [ 2 ] . It 
has been estimated that hereditary NETs repre-
sent 10–30 % of these tumors but this rate seems 
to be an underestimation  [ 2 ] . Recently, new 
imaging procedures have been developed, such 
as 68Ga-DOTATOC PET, which was reported to be 
highly sensitive in detecting NETs  [ 3 ] .
 Patients with hereditary NET syndromes inherit 
the susceptibility to develop multiple endocrine 
neoplasias, which can be associated with nonen-
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 Abstract
 ▼
 Neuroendocrine tumors (NETs) can be sporadic 
or they can arise in complex hereditary syn-
dromes. Patients with hereditary NETs can be 
identifi ed before the development of tumors by 
performing genetic screenings. The aim of the 
study was to evaluate the clinical and prognostic 
impact of a preclinical genetic screening in sub-
jects with hereditary NET syndromes. 46 sub-
jects referred for hereditary NET syndrome [22 
MEN1, 12 MEN2, 12 Familial Paragangliomatosis 
(FPGL)] were enrolled and divided in 2 groups 
(group A, 20 subjects with clinical appearance 
of NET before the genetic diagnosis; group B, 
26 subjects with genetic diagnosis of hereditary 
NET syndromes before the clinical appearance of 
NETs). The main outcome measures were sever-
ity of disease, prognosis, and survival. The rate 
of surgery for MEN1-, MEN2-, FPGL4-related 
tumors was 90 % in group A and 35 % in group 
B (p < 0.01). Both symptoms related to tumors 
and symptoms related to therapies were signifi -
cantly less frequent in group B than in group A 
(p < 0.05). Tumor stage was locally advanced or 
metastatic in 50 % of group A and in no one of 
group B (p < 0.01). The mortality rate was 25 % 
in group A and 0 % in group B (p < 0.05). An early 
genetic screening for hereditary NET syndromes 
results in an improvement in clinical presenta-
tion and morbidity. A potential impact of the 
genetic screening on the mortality rate of these 
subjects is suggested and needs to be investi-
gated in further and more appropriate studies.
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familial expressivity and genetic anticipation  [ 8 ,  9 ] . The preva-
lence of MEN1 is estimated to be 1:30 000 individuals, with the 
same distribution between males and females  [ 10 ] . The clinical 
diagnosis of MEN1 is based on the concomitant occurrence of at 
least 2 of the following tumors: parathyroid adenoma, pituitary 
adenoma, and gastroenteropancreatic (GEP)-NET. Familial 
MEN1 is defi ned as at least one MEN1-related NET plus at least 
one fi rst-degree relative with at least one of the 3 classical 
tumors or a known germline  MEN1 mutation  [ 5 ] . Typically, NETs 
associated to MEN1 rise up 2 decades before the sporadic ones. 
They are generally benign; however, both GEP-NETs and carci-
noids can be malignant.
 MEN2 or Sipple’s Syndrome (OMIM #171400) is an autosomal 
dominant disease resulting from germline mutations of the  RET 
proto-oncogene, with an estimated prevalence of 1:30 000 sub-
jects  [ 5 ] . RET is a receptor tyrosine kinase, which results to be 
activated in MEN2  [ 11 ] . MEN2 is divided in 3 clinical variants: 
a) MEN2A (medullary thyroid cancer, pheochromocytoma, pri-
mary hyperparathyroidism and cutaneous lichen amyloidosis); 
b) familial medullary thyroid cancer (FMTC); and c) MEN2B 
(medullary thyroid cancer, mucosal and intestinal ganglioneuro-
matosis, marfanoid habitus)  [ 5 ,  12 ,  13 ] . About 56 % of cases 
belong to the subtype 2 A, while the subtype 2B is the most 
aggressive with an elevated morbidity and mortality  [ 12 – 14 ] . 
MEN2 is characterized by a genotype-phenotype correlation 
 [ 12 ] .
 MEN4 is a recently discovered hereditary NET syndrome caused 
by mutations in the cyclin dependent kinase inhibitor (CDKI) 
gene  CDKN1B/p27 Kip1 . The aﬀ ected animals exhibited pheno-
typic overlap of both MEN1 and MEN2 in an autosomal recessive 
pattern of inheritance. The phenotype of the CDKN1B mutation-
positive subjects is still unclear and more aﬀ ected cases need to 
be identifi ed before any conclusions can be drawn and clinical 
management measurements can be taken  [ 15 ,  16 ] .
 Familial Paragangliomatosis (FPGLs)
 ▼
 FPGLs are a family of hereditary syndromes of susceptibility to 
multiple neuroectodermal tumors. Paragangliomas arise from 
adrenal medulla (pheochromocytomas) or extra-adrenal ganglia 
(paragangliomas) and are characterized by high vascularization 
and slow growth. In 10–50 % of the cases, paragangliomas and 
pheochromocytomas are not sporadic and arise within genetic 
disorders such as FPGLs, MEN2, NF1, VHL, and Carney Complex 
 [ 17 – 19 ] .
 There are 4 subtypes of FPGLs; only 3 of them (FPGL1, FPGL3, and 
FPGL4) are associated to known germline mutations of the genes 
encoding subunits of succinate dehydrogenase (SDH)  [ 20 ] .
 The genetic origin infl uences the natural history of NETs: this is 
particularly evident in MEN1 where the diagnosis is made 
around the sixth decade of life in sporadic tumors while it is 
anticipated of about 3 decades in hereditary tumors  [ 5 ,  8 ] . The 
identifi cation of hereditary NET syndromes is relevant to achieve 
a precocious diagnosis of the tumors and this may be important 
to prevent severe complications and unfavorable outcome. In the 
last years, it has been possible to identify a number of genes and 
molecular pathways involved in the development of NETs. Of 
consequence, some patients with an apparently sporadic tumor 
have been reclassifi ed as carriers of a hereditary NET with rele-
vant implications on the clinical course of disease and quality of 
life. Recently, the genetic screening has been reported to deter-
mine a more favorable outcome in asymptomatic subjects with 
MEN1 syndrome  [ 21 ,  22 ] .
 The aim of this study was to evaluate the clinical and prognostic 
impact of a preclinical genetic diagnosis in patients with diﬀ er-
ent hereditary NET syndromes (MEN1, MEN2, FPGL4).
 Patients and Methods
 ▼
 Patients
 Between January 2003 and December 2009, 62 subjects were 
evaluated for hereditary NET at the Department of Molecular 
and Clinical Endocrinology and Oncology of the “Federico II” 
University Hospital of Naples. They included subjects with clini-
cal, biochemical, and morphological features suggestive for a 
hereditary NET and fi rst-degree relatives of patients with hered-
itary NETs. In details, the genetic analysis was performed in 9 
patients with clinical diagnosis of MEN1 and 21 asymptomatic 
subjects fi rst-degree relatives of patients with MEN1; 5 patients 
with clinical diagnosis of medullary thyroid carcinoma and 11 
asymptomatic subjects fi rst-degree relatives of patients with 
MEN2; 6 patients with clinical diagnosis of paraganglioma and 
10 asymptomatic subjects fi rst-degree relatives of patients with 
FPGL4.
 Among the whole group genetically tested, 46 subjects (18 
males, 28 females) were diagnosed as hereditary NET: 22 (9 
males, 13 females), belonging to 9 families, were aﬀ ected with 
MEN1; 12 (3 males, 9 females), belonging to 5 families, were 
aﬀ ected with MEN2 (FMTC); and 12 (5 males, 7 females), belong-
ing to 6 families, were aﬀ ected with FPGL4.
 All women included were in premenopausal age. No patients 
have been treated with corticosteroids or other drugs known to 
induce alterations in bone mineral density.
 We did not observe phenocopies among the fi rst-degree rela-
tives of patients with MEN1, MEN2, or FPGL who were negative 
at the genetic test and so considered not aﬀ ected with MEN1, 
MEN2, or FPGL.
 The 46 subjects with hereditary NETs were divided in 2 groups: 
group A (20 subjects), patients with clinical onset of disease, and 
group B (26 subjects), carriers of gene mutations without clini-
cal symptoms at the time of the genetic diagnosis.
 All the 46 subjects with hereditary NET syndromes were clini-
cally, biochemically, and morphologically evaluated to detect 
the presence of tumors and related manifestations according to 
the specifi c NET syndrome. A clinical follow-up was performed 
every 6 months, a biochemical and morphological follow-up 
yearly (unless there were clinical or biochemical signs of disease 
onset or modifi cation). In MEN1 patients, the follow-up also 
included a duodeno-pancreatic echoendoscopy to detect non-
functioning endocrine tumors early.
 The total duration of the follow-up was 49.41 ± 3.35 (17–111) 
months for all the 46 subjects, 52.25 ± 5.7 (17–111) months for 
group A, and 47.23 ± 4.04 (21–81) months for group B.
 Genetic analysis
 Written informed consent was obtained from all subjects under-
going genetic test. Genomic DNA of patients of group A was 
extracted from peripheral blood leukocytes and the specifi c 
exons for MEN1, MEN2, or hereditary pheochromocytoma/para-
ganglioma genes ( RET ,  SDH ,  VHL ) were analyzed according to 
standard protocols  [ 23 – 25 ] . In subjects of group B, the fi rst-
degree relatives of patients with genetic diagnosis of hereditary 
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NET, genetic test was performed to detect the known mutation 
in the family.
 Among the 30 subjects genetically screened for the  MEN1 gene 
mutations, 22 of them (73 %) were positive, 8 (27 %) fi rst-degree 
relatives of MEN1 patients were negative, and considered not 
aﬀ ected with MEN1. Through  MEN1 mutation analysis the dis-
ease-causing mutations identifi ed were frameshift 317delC 
(exon 2), frameshift 335delA (exon 2), missense Trp220Arg 
(exon 4), frameshift 1061delC (exon 7), nonsense Arg527Stop 
(exon 10), frameshift 1671del11 (exon 10).
 Among the 16 subjects genetically screened for the  RET proto-
oncogene mutations, 12 of them (75 %) were positive, 4 (25 %) 
fi rst-degree relatives were negative and considered not aﬀ ected 
with MEN2. Through  RET mutation analysis the disease-causing 
mutation identifi ed was Glu768Asp (exon 13) in all unrelated 
families.
 Among the 16 subjects genetically screened for the hereditary 
pheochromocytoma/paraganglioma genes ( RET ,  VHL ,  SDHB, 
SDHC, SDHD ) mutations, 12 of them (75 %) were positive for 
 SDHB mutations, and 4 (25 %) fi rst-degree relatives were nega-
tive and considered not aﬀ ected with FPGL. Through  SDHB 
mutation analysis the disease-causing mutations identifi ed 
were nonsense Q30X (exon 2), c.183 T  > G (exon 2), c.423+1 G  > A 
(exon 4), 536–538delCAG (exon 6), c.603 G  > A (exon 6).
 Statistical analysis
 The statistical analysis was performed by SPSS for Windows ver-
sion 15.0 (SPSS, Inc., Chicago, IL). Data are reported as mean ± SEM. 
The signifi cance was set at 5 %, p < 0.05. The comparison between 
the numerical data was performed by the analysis of variance 
(ANOVA test). The comparison between the categorical data was 
performed by χ 2 -test with Yates correction and Fisher exact test 
as appropriate.
 Results
 ▼
 Prevalence
 In group A, the prevalence of at least one tumor associated to 
MEN1, MEN2, or FPGL4 syndrome was by defi nition 100 %, 
while, in group B, the prevalence of at least one tumor associated 
to the syndrome was 50 % (p < 0.001) (  ●  ▶   Table 1 ). The distribu-
tion of each type of NET in group A and in group B is shown 
in   ●  ▶   Table 1 .
 Clinical features
 Clinical features, therapies and outcome of patients with MEN1, 
MEN2, and FPGL4 are shown in   ●  ▶   Table 2 . As a whole, for 
patients with hereditary NET syndrome with clinical onset 
(group A), the percentage of patients who underwent surgery for 
MEN1-, MEN2- or FPGL4-related tumors was 90 % while for car-
riers of gene mutations (group B) it was 35 % (p < 0.01).
 At the last follow-up, tumor stage was locally advanced or meta-
static in 50 % of patients of group A and in none of the subjects of 
group B (p < 0.01). Disease activity was characterized by progres-
sion in 50 % of patients of group A and in 4 % of subjects of group 
B (p < 0.01). Tumor-associated symptoms were in 70 % of patients 
of group A and 27 % of subjects of group B (p < 0.01). Symptoms 
related to medical and/or surgical therapies were in 45 % of 
patients of group A and 12 % of subjects of group B (  ●  ▶   Table 2 ).
 The mortality rate was 25 % in group A and 0 % in group B 
(p < 0.05) (  ●  ▶   Table 2 ).
 MEN1
 The mean age at diagnosis was 45.4 ± 3.1 years in group A and 
24.2 ± 3.8 years in group B (p < 0.001). In group A, the fi rst MEN1-
related manifestation was nephrolithiasis in 67 % of cases, oste-
oporosis in 11 % of cases, peptic ulcer in 33 % of cases, headache and 
visual defects in 11 %, and pituitary hyperfunction in 22 %. In group 
B, the fi rst MEN1-related manifestation was nephrolithiasis in 23 % 
of cases, peptic ulcer in 15 % of cases, pituitary hyperfunction in 8 % 
of cases; in 62 % of cases no MEN1-related clinical manifestation 
was observed (  ●  ▶   Fig. 1 ). Hypogonadism was only reported in 2 
MEN1 patients, one male with a GH/PRL-secreting macroadenoma 
(group A) and one female aﬀ ected with a macroPRLoma (group B). 
All patients with osteoporosis/osteopenia were aﬀ ected with pri-
mary hyperparathyroidism: they were 2 patients in group A, both 
aﬀ ected with osteoporosis, both harboring a PRL-secreting pitui-
tary adenoma and one being aﬀ ected with hypogonadotropic 
hypogonadism and 3 patients in group B, all aﬀ ected with osteope-
nia, with neither PRL-secreting adenomas nor hypogonadism.
 Surgery and symptoms were more frequent in group A than in 
group B (p < 0.05). In particular, 5 subjects in group A and 2 subjects 
in group B underwent parathyroidectomy, which was total in 3 
subjects in group A and in 1 in group B, and near total in 2 in group 
A and in 1 in group B. In 4 of 6 cases that had undergone parathy-
roid surgery, partial thyroidectomy was contextually performed 
because of the presence of thyroid nodules. 2 subjects in group A 
 Table 1  Prevalence of tumors in MEN1, MEN2, and FPGL4 patients with 
clinical (group A) and pre-clinical (group B) diagnosis 
  Group A n of 
aﬀ ected pts/
total pts ( %) 
 Group B n of 
aﬀ ected pts/
total pts ( %) 
 Total n of 
aﬀ ected pts/
total pts ( %) 
 MEN1 
 Parathyroid  8/9 (88.9)  7/13 (53.8)  15/22 (68.2) 
 Pituitary  7/9 (77.8)  5/13 (38.5)  12/22 (54.5) 
 PRLoma  6/9 (66.7)  2/13 (15.4)  8/22 (36.4) 
 GHoma  0/9 (0)  0/13 (0)  0/22 (0) 
 GH-PRLoma  1/9 (11.1)  0/13 (0)  1/22 (4.5) 
 ACTHoma  0/9 (0)  0/13 (0)  0/22 (0) 
 TSHoma  0/9 (0)  0/13 (0)  0/22 (0) 
 NF  0/9 (0)  3/13 (23.1)  3/22 (13.6) 
 GEP tract  8/9 (88.9)  5/13 (38.5) **  13/22 (59.1) 
 Gastrinoma  7/9 (77.8)  2/13 (15.4)  9/22 (40.9) 
 Insulinoma  1/9 (11.1)  0/13 (0)  1/22 (4.5) 
 NF  2/9 (22.2)  4/13 (30.8)  6/22 (27.3) 
 Carcinoids  0/9 (0)  0/13 (0)  0/22 (0) 
 Thymus  0/9 (0)  0/13 (0)  0/22 (0) 
 Bronchus  0/9 (0)  0/13 (0)  0/22 (0) 
 Other site  5/9 (55.6)  0/13 (0) *  5/22 (22.7) 
 Adrenal adenoma  4/9 (44.4)  0/13 (0) **  4/22 (18.2) 
 Meningioma  2/9 (22.2)  0/13 (0)  2/22 (9.1) 
 MEN2 (FMTC) 
 MTC  5/5 (100)  5/7 (71.4)  10/12 (83.3) 
 Other tumors  0/5 (0)  0/7 (0)  0/12 (0) 
 FPGL4 
 Paraganglioma  6/6 (100)  0/6 (0) *  6/12 (50) 
 Cervical  1/6 (16.7)  0/6 (0)  1/12 (8.3) 
 Mediastinic  0/6 (0)  0/6 (0)  0/12 (0) 
 Abdominal  3/6 (50)  0/6 (0)  3/12 (25) 
 Retroperitoneal  1/6 (16.7)  0/6 (0)  1/12 (8.3) 
 Pelvic  1/6 (16.7)  0/6 (0)  1/12 (8.3) 
 Other tumors  0/6 (0)  0/6 (0)  0/12 (0) 
 *p < 0.01 (group A vs. group B);  ** p 0.05 (group A vs. group B) 
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and 2 in group B underwent pancreatic surgery, which was 1 
body-tail pancreatectomy in group A and 2 in group B and 1 duo-
deno-head pancreatectomy in group A. One subject in group A 
and none in group B underwent pituitary surgery, which was per-
formed by transsphenoidal approach. Tumor stage and mortality 
were worse in group A than in group B (p < 0.05) (  ●  ▶   Table 2 ). Pitu-
itary tumor was more frequently a macroadenoma in group A than 
in group B (p < 0.05) and GEP-NETs had more frequent complica-
tions in group A than in group B (p < 0.01) (  ●  ▶   Table 3 ).
 The mortality rate was 44 % in group A and 0 % in group B 
(p < 0.05) (  ●  ▶   Table 2 ).
 MEN2
 The mean age at diagnosis was 47.8 ± 1.9 years in group A and 
38.9 ± 4.6 years in group B. In group A, the fi rst clinical manifesta-
tion was cervical swelling, associated to elevated calcitonin 
(> 10 ng/l) and CEA (> 4 ng/ml) serum concentrations in 100 % of 
cases and lymph node metastases in 60 % of cases. In group B, the 
fi rst MEN2-related manifestation was elevated calcitonin in 43 % 
of cases, associated to thyroid nodules in 71 % of cases; there were 
neither thyroid nodules nor elevated calcitonin in 29 % of cases 
(  ●  ▶   Fig. 2 ). Tumors were at a more advanced stage and more pro-
gressive in group A than in group B (p < 0.05) (  ●  ▶   Table 2 ).
 The mortality rate was 20 % in group A and 0 % in group B 
(  ●  ▶   Table 2 ).
 FPGL4
 The mean age at diagnosis was 28.7 ± 3.5 years in group A and 
32.3 ± 5.0 years in group B. In the patients of group A, the fi rst 
clinical manifestation was a hypertensive crisis in 33 % of cases, 
acute abdomen in 17 % of cases; 50 % of patients were asympto-
matic and were diagnosed on the basis of radiologically evident 
lesions. In the subjects of group B, there were no signs of FPGL 
occurrence (  ●  ▶   Fig. 3 ). The percentage of subjects who under-
went surgery for FPGL4-related tumors was higher in group A 
than in group B (p < 0.05).
 The mortality rate was 0 % both in group A and in group B 
(  ●  ▶   Table 2 ).
 Discussion
 ▼
 The reason for a delay in the clinical diagnosis of hereditary NETs 
and the consequent frequent presentation at the time of diagno-
sis with a locally advanced or metastatic disease is that NETs are 
generally indolent, have a low proliferative index, and remain 
 Fig. 1  Clinical manifestations at onset in MEN1 
patients with clinical (group A) and pre-clinical 
(group B) diagnosis. *p < 0.01 (group A vs. 
group B). 
 Table 2  Clinical features, therapy and outcome in MEN1, MEN2, and FPGL4 patients with clinical (group A) and preclinical (group B) diagnosis 
  MEN1  MEN2  FPGL4  Total 
  Group A n of 
aﬀ ected pts/
total pts (%) 
 Group B n of 
aﬀ ected pts/
total pts (%) 
 Group A n of 
aﬀ ected pts/
total pts (%) 
 Group B n of 
aﬀ ected pts/
total pts (%) 
 Group A n of 
aﬀ ected pts/
total pts (%) 
 Group B n of 
aﬀ ected pts/
total ts (%) 
 Group A n of 
aﬀ ected pts/
total pts (%) 
 Group B n of 
aﬀ ected pts/
total pts (%) 
 Surgery  7/9 (77.8)  3/13 ** (23.1)  5/5 (100)  5/7 (71.4)  6/6 (100)  0/6 * (0)  18/20 (90)  8/26 * (30.8) 
 Tumor stage # 
 Localized  5/9 (55.6)  13/13 ** (100)  1/5 (20)  7/7 ** (100)  4/6 (66.7)  6/6 (100)  10/20 (50)  24/26 * (92.3) 
 Advanced  4/9 (44.4)  0/13 ** (0)  4/5 (80)  0/7 ** (0)  2/6 (33.3)  0/6 (0)  10/20 (50)  0/26 * (0) 
 Disease activity # 
 Remission  0/9 (0 %)  4/13 (30.8)  1/5 (20)  2/7 (28.6)  4/6 (66.7)  6/6 (100)  5/20 (25)  12/26 (46.2) 
 Progression  4/9 (44.4)  1/13 (7.7)  4/5 (80)  0/7 ** (0)  2/6 (33.3)  0/6 (0)  10/20 (50)  1/26 * (4) 
 Stability  5/9 (55.6)  8/13 (61.5)  0/5 (0)  3/7 (42.9)  0/6 (0)  0/6 (0)  5/20 (24)  11/26 (42.3) 
 Symptoms # 
 Related to tumor  8/9 (88.9)  7/13 (53.8)  3/5 (60)  0/7 (0)  3/6 (50)  0/6 (0)  14/20 (70)  7/26 * (27) 
 Related to therapy  2/9 (22.2)  0/13 ** (0)  4/5 (80)  3/7 (42.9)  3/6 (50)  0/6 (0)  9/20 (45)  3/26 (11.5) 
 No symptoms  0/9 (0 %)  5/13 ** (38.5)  0/5 (0)  2/7 (28.6)  4/6 (66.7)  6/6 (100)  4/20 (20)  13/26 (50) 
 Mortality  4/9 (44.4)  0/13 ** (0)  1/5 (20)  0/7 (0)  0/6 (0)  0/6 (0)  5/20 (25)  0/26 ** (0) 
 *p < 0.01 (group A vs. group B); **p < 0.05 (group A vs. group B);  # at the last follow-up 
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asymptomatic for long time. Nowadays, the improved knowl-
edge on NET biology and genetics oﬀ ers the possibility to achieve 
an early diagnosis of hereditary NETs, through the genetic 
screening, thus preventing the evolution toward a clinically, bio-
chemically, or radiologically evident tumor  [ 26 – 31 ] . In this 
attempt, periodical evaluations in reference health centers are 
necessary in subjects with preclinical hereditary NETs, espe-
cially young subjects, to detect tumors early and prevent com-
plications and risk of malignant transformation  [ 5 ,  8 ,  20 ,  32 ] .
 Fig. 2  Clinical manifestations at onset in MEN2 
patients with clinical (group A) and preclinical 
(group B) diagnosis. *p < 0.01 (group A vs. group B). 
 Fig. 3  Clinical manifestations at onset in FPGL4 
patients with clinical (group A) and preclinical 
(group B) diagnosis. *p < 0.01 (group A vs. group B). 
 
 Tumor site  Group A  Group B 
 Parathyroid 
 Number of adenomas  2.5 ± 0.3 (2–4)  2.0 ± 0.2 (1–3) 
 Parathyroid  n of aﬀ ected pts/total pts ( %)  n of aﬀ ected pts/total pts ( %) 
 Complications  5/9 (55.6)  5/13 (38.5) 
 Nephrolithiasis  5/9 (55.6)  2/13 (15.4) 
 Osteopenia/osteoporosis  2/9 (22.2)  3/13 (23.1) 
 Renal failure  1/9 (11.1)  0/13 (0) 
 Pituitary  n of aﬀ ected pts/total pts ( %)  n of aﬀ ected pts/total pts ( %) 
 Macroadenoma  5/9 (55.6)  1/13 (7.7) ** 
 Microadenoma  2/9 (22.2)  4/13 (30.8) 
 Complications  7/9 (77.8)  5/13 (38.5) 
 Loco-regional features #  3/9 (33.3)  1/13 (7.7) 
 Pituitary hypersecretion ##  7/9 (77.8)  2/13 (15.4) * 
 GEP tract  n of aﬀ ected pts/total pts ( %)  n of aﬀ ected pts/total pts ( %) 
 Number of neoplasias  4.4 ± 1.8 (1–16)  2.5 ± 0.9 (1–7) 
 Hyperfunctioning syndrome  7/9 (77.8)  2/13 (15.4) * 
 Complications  7/9 (77.8)  2/13 (15.4) * 
 Peptic ulcer  7/9 (77.8)  2/13 (15.4) * 
 Hypoglycemia  1/9 (11.1)  0/13 (0) 
 Tumor mass  4/9 (44.4)  0/13 (0) ** 
 *p < 0.01 (group A vs. group B); **p < 0.05 (group A vs. group B);  # Headache, visual defects;  ## Hyperprolactinemia, acromegaly 
 Table 3  Clinical features in 
MEN1 patients with clinical 
(group A) and preclinical 
(group B) diagnosis
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 In the last years, the growing number of subjects with heredi-
tary NET who is diagnosed at a preclinical stage is changing the 
clinical picture of these tumors. Until now the clinical features 
and natural history of hereditary NETs were based on data from 
patients with clinical evidence of disease. With the identifi ca-
tion of specifi c genes responsible for the development of heredi-
tary NETs, more and more subjects are recognized to be carriers 
of NET-related gene mutations. Preclinical genetic screening in 
asymptomatic fi rst-degree relatives of patients with hereditary 
NET syndromes leads to detect these neoplasias at an early stage, 
even when subjects are still asymptomatic.
 The impact of genetic screening on the management and out-
come of asymptomatic subjects genetically diagnosed for MEN1 
has been recently evaluated in 2 studies  [ 21 ,  22 ] . These studies 
highlighted that genetic screening in asymptomatic MEN1 sub-
jects before the clinical appearance of NETs is associated with an 
improvement of the long-term outcome. However, these conclu-
sions have been achieved only for one of the hereditary syn-
dromes associated with NETs. There are no studies evaluating 
the impact of genetic screening in patients with hereditary NET 
syndromes as a whole group, including diﬀ erent types of syn-
drome.
 The current study has evaluated patients with MEN1, MEN2, and 
FPGL highlighting that in patients with hereditary NET syn-
dromes, regardless from the type of syndrome, an early diagno-
sis and treatment of potentially malignant tumors is necessary 
to reduce tumor-related morbidity. The rationale for grouping 
diﬀ erent patients with diﬀ erent hereditary NETs is to emphasize 
the role of genetic screening in hereditary NET syndromes, 
which have all in common the tendency to develop NETs along 
the life and the possibility to identify the syndrome before the 
clinical appearance of the disease.
 The mortality rate was signifi cantly higher in subjects with clin-
ical appearance of NET than in those with genetic diagnosis of 
hereditary NET syndromes before the clinical appearance of 
NETs. Although the evaluation of mortality is limited by the fact 
that subjects in the former group were older than those in the 
latter group, these data suggest that the genetic screening poten-
tially impacts on mortality in hereditary NET syndromes. This 
represents a relevant point for further and more appropriate 
investigations.
 Patients clinically diagnosed require more aggressive and haz-
ardous therapies, more frequent and invasive medical examina-
tions than those who were identifi ed at the genetic screening in 
the absence of clinical evidence of disease. In addition, the 
former group has worse outcome and lower rate of cure than the 
former one.
 Another relevant point is that patients with hereditary NET syn-
dromes need to be followed in experienced centers which should 
represent a landmark for this pathology in a specifi c geographic 
region. This is because MEN1, MEN2, FPGL as well as other NET, 
and non-NET genetic syndromes may vary in gene penetrance 
and expressivity between populations from diﬀ erent geographic 
areas  [ 5 ,  13 ,  17 ,  25 ] . About 6 million inhabitants of the Campania 
region (including Naples and surrounding areas) represent the 
population which refers to our center for patients with NET, 
which has already identifi ed 46 patients with hereditary NET 
syndrome since the start of its activity in 2003. The series of 
patients described here reveals some diﬀ erences as compared to 
data reported in previous studies concerning tumor distribution 
in patients with MEN1 and FPGL4 but not in those with MEN2. 
In MEN1, the prevalence of pituitary adenomas and GEP-NETs 
observed in the current study was higher than that previously 
observed. Then the prevalence of carcinoids (thymic or bron-
chial) was lower while the prevalence of adrenal cortical adeno-
mas and meningiomas was higher than in previous studies 
 [ 5 ,  8 ,  21 ,  22 ] . Hyperparathyroidism was the fi rst manifestation in 
the majority of cases. Anyway a pancreatic NET, 4 cm in size, was 
the fi rst manifestation in a young totally asymptomatic woman, 
daughter of a MEN1 index case. Of consequence, the periodical 
evaluation for hyperparathyroidism onset only in MEN1 subjects 
without clinical manifestations at the diagnosis is not suﬃ  cient 
and these patients need to be more extensively evaluated in the 
course of their periodical follow-up, confi rming previous obser-
vations  [ 5 ,  22 ] . The impairment of bone mineral density was 
consistent with osteoporosis in group A and osteopenia in group 
B. It is likely that hyperprolactinemia may in part explain the 
severity of loss in bone mineral density in patients of group A, 
however the duration of hyperparathyroidism, which was higher 
in group A than in group B, is the most reliable explanation. In 
FPGL4 patients, the peculiar trait of the present series was the 
absence of adrenal paragangliomas (pheochromocytomas) in 
association with extra-adrenal paragangliomas.
 In conclusion, this study evaluated the clinical and prognostic 
impact of genetic screening in patients with hereditary NETs 
associated to MEN1, MEN2, and FPGL4, highlighting that an early 
genetic diagnosis in asymptomatic subjects is recommended to 
identify subjects at risk to develop one of the above mentioned 
syndromes as early as possible before the occurrence of clinical 
manifestations, in order to improve their long-term outcome 
and to ensure a survival and quality of life similar to that 
observed in the general population. Based on data from large 
series of patients followed in experienced centers, diagnostic 
and therapeutic algorithms have to be elaborated to improve the 
management of patients with hereditary NET syndromes.
 Acknowledgements
 ▼
 We are grateful to all patients and their family members who 
were included in this study and to M. L. Brandi and A. Falchetti, 
Department of Internal Medicine, University of Florence for the 
genetic test of MEN1; V. Colantuoni and L. Circelli, Department 
of Biochemistry and Medical Biotechnology and Genetic Engi-
neering Center, CEINGE of Naples for the genetic test of RET; M. 
Mannelli and T. Ercolino, Department of Clinical Physiopathol-
ogy, University of Florence for the genetic test of SDH. This study 
was partially supported by a grant from the Italian Minister of 
Research and University in Rome (no. 2008LFK7J5).
 References
1  Yao  J C ,  Hassan  M ,  Phan  A ,  Dagohoy  C ,  Leary  C ,  Mares  J E ,  Abdalla  E K , 
 Fleming  J B ,  Vauthey  J N ,  Rashid  A ,  Evans  D B .   One hundred years after 
“carcinoid”: epidemiology of and prognostic factors for neuroendo-
crine tumors in 35,825 cases in the United States .   J Clin Oncol  2008 ; 
 26 :  6012 – 6013 
2  Karges  W ,  Adler  G .   Clinical genetics of neuroendocrine tumors .   Med 
Klin (Munich)  2003 ;  98 :  712 – 716 
3  Müssig  K ,  Oksüz  M O ,  Dudziak  K ,  Ueberberg  B ,  Wehrmann  M ,  Horger  M , 
 Schulz  S ,  Häring  H U ,  Pfannenberg  C ,  Bares  R ,  Gallwitz  B ,  Petersenn  S . 
 Association of somatostatin receptor 2 immunohistochemical expres-
sion with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC 
PET/CT in neuroendocrine tumors .   Horm Metab Res  2010 ;  42 :  599 – 606 
4  Knudson  A G  Jr .   Mutation and cancer: statistical study of retinoblas-
toma .   Proc Natl Acad Sci USA  1987 ;  68 :  820 – 823 
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
 
800 Humans, Clinical
 Ramundo V et al. Impact of Genetics in NET … Horm Metab Res 2011; 43: 794–800 
5  Brandi  M L ,  Gagel  R F ,  Angeli  A ,  Bilezikian  J P ,  Beck-Peccoz  P ,  Bordi  C , 
 Conte-Devolx  B ,  Falchetti  A ,  Gheri  R J ,  Libroia  A ,  Lips  CJ M ,  Lombardi  G , 
 Mannelli  M ,  Pacini  F ,  Ponder  BA J ,  Raue  F ,  Skogseid  B ,  Tamburano  G , 
 Thakker  R H ,  Thompson  N W ,  Tomassetti  P ,  Tonelli  F ,  Wells  S A ,  Marx  S J . 
 Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 .   J 
Clin Endocrinol Metab  2001 ;  86 :  5658 – 5671 
6  Sakorafas  G H ,  Friess  H ,  Peros  G .   The genetic basis of hereditary med-
ullary thyroid cancer: clinical implications for the surgeon, with a 
particular emphasis on the role of prophylactic thyroidectomy . 
 Endocr Relat Cancer  2008 ;  15 :  871 – 884 
7  American Thyroid Association Guidelines Task Force , Kloos  R T ,  Eng  C , 
 Evans  D B ,  Francis  G L ,  Gagel  R F ,  Gharib  H ,  Moley  J F ,  Pacini  F ,  Ringel  M D , 
 Schlumberger  M ,  Wells  S A  Jr .   Medullary thyroid cancer: management 
guidelines of the American Thyroid Association .   Thyroid  2009 ;  19 : 
 565 – 612 
8  Marx  S ,  Spiegel  A M ,  Skarulis  M C ,  Doppman  J L ,  Collins  F S ,  Liotta  L A . 
 Multiple endocrine neoplasia type 1: clinical and genetic topics .   Ann 
Intern Med  1998 ;  129 :  484 – 494 
9  Wermer  P .   Genetic aspects of adenomatosis of endocrine glands .   Am 
J Med  1954 ;  16 :  363 – 371 
10  Busygina  V ,  Bale  A E .   Multiple Endocrine Neoplasia Type 1 (MEN1) as 
a Cancer Predisposition Syndrome: Clues into the Mechanisms of 
MEN1-related Carcinogenesis .   Yale J Biol Med  2006 ;  79 :  105 – 114 
11  Powers  J F ,  Picard  K L ,  Tischler  A S .   RET expression and neuron-like dif-
ferentiation of pheochromocytoma and normal chromaﬃ  n cells . 
 Horm Metab Res  2009 ;  41 :  710 – 714 
12  Raue  F ,  Frank-Raue  K .   Multiple endocrine neoplasia type 2: 2007 
update .   Horm Res  2007 ;  5 :  101 – 114 
13  Romei  C ,  Mariotti  S ,  Fugazzola  L ,  Taccaliti  A ,  Pacini  F ,  Opocher  G ,  Mian 
 C ,  Castellano  M ,  degli Uberti  E ,  Ceccherini  I ,  Cremonini  N ,  Seregni  E , 
 Orlandi  F ,  Ferolla  P ,  Puxeddu  E ,  Giorgino  F ,  Colao  A ,  Loli  P ,  Bondi  F ,  Cosci 
 B ,  Bottici  V ,  Cappai  A ,  Pinna  G ,  Persani  L ,  Verga  U ,  Boscaro  M ,  Castagna 
 M G ,  Cappelli  C ,  Zatelli  M C ,  Faggiano  A ,  Francia  G ,  Brandi  M L ,  Falchetti 
 A ,  Pinchera  A ,  Elisei  R .  ItaMEN network ,  Multiple endocrine neoplasia 
type 2 syndromes (MEN 2): results from the ItaMEN network analy-
sis on the prevalence of diﬀ erent genotypes and phenotypes .   Eur J 
Endocrinol  2010 ;  163 :  301 – 308 
14  Frank-Raue  K ,  Rondot  S ,  Raue  F. .   Molecular genetics and phenomics 
of RET mutations: Impact on prognosis of MTC .   Mol Cell Endocrinol 
 2010 ;  322 :  2 – 7 
15  Pellegata  N S ,  Quintanilla-Martinez  L ,  Siggelkow  H ,  Samson  E ,  Bink  K , 
 Höfl er  H ,  Fend  F ,  Graw  J ,  Atkinson  M J .   Germ-line mutations in p27Kip1 
cause a multiple endocrine neoplasia syndrome in rats and humans . 
 Proc Natl Acad Sci U S A  2006 ;  103 :  15558 – 15563 
16  Georgitsi  M .   MEN-4 and other multiple endocrine neoplasias due to 
cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) 
mutations .   Best Pract Res Clin Endocrinol Metab  2010 ;  24 :  425 – 437 
17  Young  W F  Jr .   Paragangliomas: clinical overview .   Ann NY Acad Sci 
 2006 ;  1073 :  21 – 29 
18  Benn  D E ,  Robinson  B G .   Genetic basis of phaeochromocytoma and par-
aganglioma .   Best Pract Res Clin Endocrinol Metab  2006 ;  20 :  435 – 450 
19  Boedeker  C C ,  Neumann  H P ,  Oﬀ ergeld  C ,  Maier  W ,  Falcioni  M ,  Berlis  A , 
 Schipper  J .   Clinical features of paraganglioma syndromes .   Skull Base 
 2009 ;  19 :  17 – 25 
20  Mhatre  A N ,  Li  Y ,  Feng  L ,  Gasperin  A ,  Lalwani  A K .   SDHB, SDHC, and 
SDHD mutation screen in sporadic and familial head and neck para-
gangliomas .   Clin Genet  2004 ;  66 :  461 – 466 
21  Lourenco  D M  Jr ,  Toledo  R A ,  Coutinho  F L ,  Margarido  L C ,  Siqueira  SA C , 
 Cortina  M A ,  Montenegro  F L ,  Machado  M C ,  Toledo  S P .   The impact of 
clinical and genetic screenings on the management of the multiple 
endocrine neoplasia type 1 .   CLINICS  2007 ;  62 :  465 – 476 
22  Pieterman  C R ,  Schreinemakers  J M ,  Koppeschaar  H P ,  Vriens  M R ,  Rinkes 
 I H ,  Zonnenberg  B A ,  van der Luijt  R B ,  Valk  G D .   Multiple endocrine neo-
plasia type 1 (MEN1): its manifestations and eﬀ ect of genetic screen-
ing on clinical outcome .   Clin Endocrinol (Oxf)  2009 ;  70 :  575 – 581 
23  Balogh  K ,  Patócs  A ,  Majnik  J ,  Rácz  K ,  Hunyady  L .   Genetic screening 
methods for the detection of mutations responsible for multiple endo-
crine neoplasia type 1 .   Mol Genet Metab  2004 ;  83 :  74 – 81 
24  Quadro  L ,  Panariello  L ,  Salvatore  D ,  Carlomagno  F ,  Del Prete  M ,  Nun-
ziata  V ,  Colantuoni  V ,  Di Giovanni  G ,  Brandi  M L ,  Mannelli  M .   Frequent 
RET protooncogene mutations in multiple endocrine neoplasia type 
2A .   J Clin Endocrinol Metab  1994 ;  79 :  590 – 594 
25  Waldmann  J ,  Langer  P ,  Habbe  N ,  Fendrich  V ,  Ramaswamy  A ,  Rothmund 
 M ,  Bartsch  D K ,  Slater  E P .   Mutations and polymorphisms in the SDHB, 
SDHD, VHL, and RET genes in sporadic and familial pheochromocy-
tomas .   Endocrine  2009 ;  353 :  347 – 355 
26  Chandrasekharappa  S C ,  Guru  S C ,  Manickam  P ,  Olufemi  S E ,  Collins  F S , 
 Emmert-Buck  M R ,  Debelenko  L V ,  Zhuang  Z ,  Lubensky  I A ,  Liotta  L A , 
 Crabtree  J S ,  Wang  Y ,  Roe  B A ,  Weisemann  J ,  Boguski  M S ,  Agarwal  S K , 
 Kester  M B ,  Kim  Y S ,  Heppner  C ,  Dong  Q ,  Spiegel  A M ,  Burns  A L ,  Marx  S J . 
 Positional cloning of the gene for multiple endocrine neoplasia-type 
1 .   Science  1997 ;  276 :  404 – 407 
27  Donis-Keller  H ,  Dou  S ,  Chi  D ,  Carlson  K M ,  Toshima  K ,  Lairmore  T C ,  Howe 
 J R ,  Moley  J F ,  Goodfellow  P ,  Wells  S A  Jr .   Mutations in the RET proto-
oncogene are associated with MEN 2A and FMTC .   Hum Mol Genet 
 1993 ;  2 :  851 – 856 
28  Mulligan  L M ,  Kwok  J B ,  Healey  C S ,  Elsdon  M J ,  Eng  C ,  Gardner  E ,  Love  D R , 
 Mole  S E ,  Moore  J K ,  Papi  L ,  Ponder  M A ,  Telenius  H ,  Tunnacliﬀ e  A ,  Ponder 
 B A .   Germ-line mutations of the RET proto-oncogene in multiple 
endocrine neoplasia type 2A .   Nature  1993 ;  363 :  458 – 460 
29  Niemann  S ,  Müller  U .   Mutations in SDHC cause autosomal dominant 
paraganglioma, type 3 .   Nat Genet  2000 ;  26 :  268 – 270 
30  Astuti  D ,  Latif  F ,  Dallol  A ,  Dahia  P L ,  Douglas  F ,  George  E ,  Sköldberg  F , 
 Husebye  E S ,  Eng  C ,  Maher  E R .   Gene mutations in the succinate dehy-
drogenase subunit SDHB cause susceptibility to familial pheochromo-
cytoma and to familial paraganglioma .   Am J Hum Genet  2001 ;  69 : 
 49 – 54 
31  Müller  U ,  Troidl  C ,  Niemann  S .   SDHC mutations in hereditary para-
ganglioma/pheochromocytoma .   Fam Cancer  2005 ;  4 :  9 – 12 
32  Chrisoulidou  A ,  Kaltsas  G ,  Ilias  I ,  Grossman  A B .   The diagnosis and 
management of malignant phaeochromocytoma and paraganglioma . 
 Endocr Relat Cancer  2007 ;  14 :  569 – 585 
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
 
Copyright of Hormone & Metabolic Research is the property of Georg Thieme Verlag Stuttgart and its content
may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express
written permission. However, users may print, download, or email articles for individual use.
